
Karl Pfleger
Aging biotechnology investor and creator of AgingBiotech.info. Exclusively invests in the aging/longevity sector with 15+ portfolio companies targeting damage repair approaches.
Top 3 podcasts with Karl Pfleger
Ranked by the Snipd community

Sep 18, 2024 • 45min
Rejuvenation biotech - progress and potential, with Karl Pfleger
Karl Pfleger, an angel investor and creator of Aging Biotech Info, dives into the exciting world of rejuvenation biotechnology. He shares insights on the rapid advancements in the field, including breakthroughs in epigenetic reprogramming and stem cell therapies. Karl discusses the role of AI in streamlining clinical trials and the importance of investors in combating age-related diseases. He also explores the concept of longevity escape velocity and how individuals can contribute to this innovative sector.

Jul 23, 2025 • 1h 19min
Karl Pfleger Explains the Aging Biotech Explosion
Karl Pfleger, an aging biotechnology investor and creator of AgingBiotech.info, dives into the explosive growth of aging therapeutics. He distinguishes between interventions that slow aging and rejuvenation strategies that repair damage. Karl shares insights on promising therapies like senolytics and epigenetic reprogramming, while cautioning about the limitations of current aging clocks and popular weight-loss drugs. Highlighting recent FDA approvals and the necessity of a multi-target strategy for longevity, he also emphasizes the foundational role of diet, exercise, and sleep in maximizing healthspan.

Jul 5, 2024 • 49min
What This Longevity Investor Knows That You Don't | Karl Pfleger, Founder of AgingBiotech.info, Co-Hosted with Dr. Greg Bailey, Chairman of Juvenescence
Karl Pfleger, founder of AgingBiotech.info and a former Google researcher, dives deep into the rapidly evolving longevity biotech landscape. He discusses the lucrative opportunities in aging-related investments, highlighting how targeting aging could revolutionize health care. Pfleger stresses the importance of understanding mechanisms of action and shares his investment strategies. He also emphasizes the promise of senolytics, or senescent cell clearance, as a leading frontier. For aspiring investors, he recommends diving into conferences and varied resources for informed decisions.